Nature Medicine：首款可缓解偏头痛发作前严重症状的药物

Core Viewpoint - The article discusses the advancements in migraine treatment, particularly focusing on the drug Ubrogepant, which has shown potential in alleviating prodromal symptoms before migraine attacks, marking a significant development in migraine management [1][2]. Group 1: Migraine Overview - Migraine is a common neurological disorder characterized by debilitating attacks that include headache and brain function impairment, with recognized phases: prodromal, aura, headache, and postdrome [1]. - Symptoms during the prodromal and aura phases can include sensitivity to light and sound, nausea, neck pain, and dizziness, leading to significant functional impairment for migraine sufferers [1]. Group 2: Ubrogepant's Clinical Research - A large-scale, randomized, placebo-controlled phase 3 clinical trial published in Nature Medicine demonstrated that Ubrogepant can reduce common non-headache symptoms during the prodromal phase of migraines [2][4]. - The study involved 438 participants aged 18-75 with a history of migraines, who were administered 100 mg of Ubrogepant or a placebo after the onset of prodromal symptoms [4]. Group 3: Efficacy of Ubrogepant - Results indicated that Ubrogepant significantly improved attention, reduced photophobia, fatigue, and neck pain within hours of administration compared to the placebo group [4][5]. - Specifically, 19.5% of participants in the Ubrogepant group did not experience photophobia after 2 hours, compared to 12.5% in the placebo group; 27.3% versus 16.8% for fatigue after 3 hours; and 50.7% versus 35.8% for phonophobia after 4 hours [5]. Group 4: Implications for Treatment - The findings suggest that taking Ubrogepant during the prodromal phase may effectively alleviate common symptoms, with improvements observable as soon as one hour after administration [6].